Specifically, the annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 PV carriers, increasing 10-year cumulative risk up to 13–40% [1,12,13]. This evidence concerns the gene BRCA2 and breast cancer.